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Abstract: Colorectal cancer (CRC) is a very common disease with a high rate of mortality around the world, representing the second 
most frequent cause of cancer-related death. As the majority of patients are diagnosed with advanced cancer with a subsequent low five-
year survival rate (10%), it is imperative to develop new strategies to treat this challenging patient population. Traditionally, patients 
sion. But despite the therapeutic advances achieved with combination chemotherapy regimens, particularly FOLFOX and FOLFIRI, 
However, progress has been achieved over recent years. The most relevant relates to the approval of several new effective therapeutic 
drugs, such as monoclonal antibodies, which have greatly improved the outcomes for metastatic disease. The last agent approved has 
been panitumumab, which has been designed to target the epidermal growth factor receptor molecular pathway involved in the appear-
ance and spread of cancer.
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received successive lines of chemotherapy and discontinued the treatment or switched to a different one in the event of disease progres-
considerable research has been necessary to further optimize chemotherapy for patients with metastatic colorectal cancer (mCRC).
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Background
Anyone  who  treats  metastatic  colorectal  cancer 
(mCRC) will be happy to read the review by Lindsey 
and Jimeno,1 which is focused on panitumumab.
Colorectal cancer (CRC) is a very common disease 
with a high rate of mortality around the world, repre-
senting the second cause of cancer-related death.2 As 
the majority of patients are diagnosed with advanced 
cancer with a subsequent low five-year survival rate 
(10%), it is imperative to develop new strategies to 
treat this challenging patient population.3 Tradition-
ally,  patients  received  succesives  lines  of  chemo-
therapy and discontinued the treatment or switched 
to a different one in the event of disease progression. 
But despite the therapeutic advances achieved with 
combination  chemotherapy  regimens,  particularly 
FOLFOX and FOLFIRI, considerable research has 
been neccesary to further optimize chemotherapy for 
patients with mCRC.3 However, considerable prog-
ress has been achieved over recent years.1 The most 
relevant relates to the approval of several new effec-
tive therapeutic drugs, such as monoclonal antibod-
ies, which have greatly improved the outcomes for 
metastatic disease. These agents have been designed 
to target the relevant molecular pathways involved in 
the appearance and spread of cancer, as Drs Lindsey 
and Jimeno have stated in their article.1
Monoclonal Antibodies 
for Treating mcRc
Bevacizumab
Several monoclonal antibodies have been approved 
for treating mCRC. The two first approved by the 
US Food and Drug Administration (FDA) were beva-
cizumab and cetuximab. The first of these is a human-
ized monoclonal antibody directed against vascular 
endothelial growth factor (VEGF), which is a soluble 
protein that stimulates angiogenesis.4,5 This agent has 
been  evaluated  in  combination  with  chemotherapy 
and it has been well tolerated, with reversible hyper-
tension and proteinuria representing two of the most 
common toxicities. Nonetheless, rare yet serious side 
effects have been observed, such as bowel perforation 
and serious bleeding or arterial embolic events.6–8
Initial  studies  demonstrated  improvements 
in  tumor  response  rate  (RR)  and  progression-
free    survival  (PFS)  when  bevacizumab  is  added 
to    fluorouracil  and  leucovorin.9,10  Subsequent 
randomized trials have shown tha bevacizumab is 
able to prolong median overall survival (OS) when 
administered in combination with IFL as a first line 
or with FOLFOX after the failure of a prior regimen 
that  contains  irinotecan.11,12  Further  studies  have 
confirmed improved RR and PFS with the addition 
of bevacizumab to FOLFIRI or FOLFOX in patients 
with untreated mCRC.13,14
Cetuximab
Cetuximab,  a  chimeric  IgG1  immunoglobulin, 
has been the first epidermal growth factor recep-
tor (EGFR) inhibitor approved for the treatment of 
CRC.1 Cetuximab binds specifically to the extra-
cellular domain of EGFR with a binding affinity 
greater than that of EGF or TGF, and it competi-
tively inhibits binding of these ligands. This union 
with  EGFR  induces  receptor  internalization  and 
degradation, thus reducing EGFR binding capacity 
and its potential for downstream growth and sur-
vival signaling. This monoclonal antibody produced 
a significant increase in RR when added to irinote-
can in irinotecan-refractory patients.15 These studies 
have confirmed a tumor RR of approximately 10% 
with cetuximab alone and 20% when it is added to 
irinotecan, indicating cetuximab’s ability of over-
coming  irinotecan  resistance  in  tumor  cells.15  In 
a study of patients whose disease had progressed 
on a fluoropyrimidine, irinotecan, and oxaliplatin 
regimen, weekly cetuximab demonstrated improve-
ments in PFS and OS survival (6.1 vs. 4.6 months) 
when compared to those treated with best support-
ive care alone.16
Two further studies assessed the addition of cetux-
imab to first-line regimens. The Cancer and Leukemia 
Group B CALGB trial has detected an improvement 
in tumor RR with cetuximab plus either FOLFIRI 
or  FOLFOX.17  On  the  other  hand,  the  CRYSTAL 
trial,  which  compared  FOLFIRI  with  and  without 
cetuximab,  demonstrated  improvements  in  tumor 
RR (47% vs. 39%) and PFS (median 8.9 months vs. 
8.0 months), among patients receiving the two drugs 
in combination.18
All these results have supported the inclusion of 
cetuximab in first-line treatment protocols, although Metastatic colorectal cancer: a commentary
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it is currently unknown how these   regimens   compare 
with treatments containing bevacizumab. To answer 
this  question,  several  ongoing  studies  have  been 
designed and we hope to have the results in the near 
future.
Panitumumab
The last monoclonal antibody introduced in the thera-
peutic arsenal to treat this disease has been panitu-
mumab, which also targets the EGFR.
As Lindsey and Jimeno have explained in their 
article, panitumumab has shown similar single agent 
activity  to  cetuximab  in  mCRC  under  a  biweekly 
administration schedule. In an initial study, 9% of 
patients  whose  cancers  had  progressed  after  treat-
ment with fluorouracil and either irinotecan or oxali-
platin experienced a tumor response to this agent.19 
Other studies, such as the trial by van Cutsem et al20 
in  which  463  patients  whose  disease  progressed 
after fluoropyrimidine-irinotecan-oxaliplatin regimens, 
were treated with either single-agent panitumumab 
or the best supportive care. The patients given pani-
tumumab  demonstrated  an  improved  PFS  when 
compared with best supportive care (median, 8.0 vs. 
7.3 weeks), similar to the improvement previously 
reported with cetuximab. But OS was not signifi-
cantly different between both groups. This fact has 
been explained by the crossover from the best sup-
portive care alone to panitumumab after progression, 
which  could  confound  the  results. An  exploratory 
analysis excluding crossover data has been done and 
supports this hypothesis.20
Based on the positive results as a monotherapy 
in advanced line, additional studies have been per-
formed to evaluate panitumumab as a part of a com-
bination regimen. The PACCE study21 (Panitumumab 
Advanced Colorectal Cancer Evaluation) compared 
bevacizumab and oxaliplatin-based or bevacizumab 
and irinotecan-based regimens with and without pani-
tumumab at a dose of 6 mg/kg every two weeks. Interim 
data have shown shorter PFS (8.8 vs. 10.5 months) 
and increased grade 4 toxicity in the panitumumab, 
oxaliplatin and bevacizumab group. Because of these 
results,  the  PACCE  study  was  stopped. Additional 
results from each arm of treatment demonstrated a 
median PFS of 10 months with panitumumab versus 
11.4 months with the standard therapy with a similar 
RR (46% versus 48%). The irinotecan group showed 
at PFS of 10.1 months in the panitumumab group and 
11.7 with the standard therapy, without any signifi-
cant difference in RR. In both analyses, it was dem-
onstrated that significant intolerable adverse events 
increased in the panitumumab groups, so the use of 
panitumumab in combination with bevacizumab was 
not recommended.21
The combination of panitumumab with FOLFOX 
for first-line treatment has been investigated in a ran-
domized study where 1,183 patients were random-
ized  to  FOLFOX4  with  panitumumab  every  two 
weeks versus FOLFOX4 alone. Patients with wild-
type KRAS status (see below) in the panitumumab 
group shown a median PFS of 9.6 months and a RR 
of 55% compared to a PFS of 8 months and a RR 
48% in patients with unmutated KRAS treated with 
FOLFOX4 alone.22
Other combinations with different chemotherapy 
regimens  are  ongoing.  Studies  evaluating  panitu-
mumab as part of combination therapy in the sec-
ond-line setting have also been performed. Patients 
in the combination arm with wild-type KRAS were 
found to have a longer PFS of 5.9 months compared 
to 3.9 months in the monotherapy group. OS was also 
significantly increased in the FOLFIRI/panitumumab 
group23 with 14.5 versus 12.5 months in the wild-type 
KRAS group. No significant difference in PFS or OS 
was noted in patients with KRAS mutations.
The combination of panitumumab and XELOX 
in the second-line, or its use as part of combination 
chemotherapy  in  the  third-line  setting,  are  pres-
ently being studied. On the other hand, there is an 
important  point  to  evaluate:  neoadjuvant  therapy. 
This field is also being studied. A small retrospec-
tive study of CRC patients treated with FOLFOX 
and panitumumab or cetuximab prior to resection 
of  liver  metastases  was  performed.  The  results 
were encouraging, with a partial response in 10 of 
12 patients (83%) and stable disease in the remain-
ing two patients. The authors have concluded that 
although the study is small, a pre-operative combi-
nation of panitumumab with FOLFOX and an EGFR 
inhibitor is associated with a high response rate and 
may increase resectability rates.24 Others combina-
tions are being studied in patients with unresectable 
liver metastases.Uña Cidón
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All these data are promising, although there is still 
the need to determine the best timing or combination, 
or the optimal sequence of administration to use in 
patients with mCRC. On the other hand, all these ben-
efits have to be weighted against their side effects, 
mainly  because  only  a  subset  of  patients’  tumors 
treated with cetuximab or panitumumab will respond 
to these drugs.
The most important adverse events related to these 
drugs are acneiform rash, hypomagnesemia and infu-
sion  reactions.1  The  relevance  of  these  secondary 
effects is related not only to the patient´s quality of 
life, but to the ability to predict their response to anti-
EGFR.
In this way, the presence and grade of an acnei-
form rash have been positively associated with an 
improved RR among patients with mCRC.1 Although 
this fact is very important, there are some patients 
with this toxicity who do not experience a response 
to these treatments.
This fact has lead to further research to identify 
predictive markers of response and outcome, partic-
ularly with these new biologic agents, and prospec-
tive clinical trials will be required to validate these 
markers.
potential predictive Tumor 
characteristics
Two such tumor characteristics have emerged from 
initial studies:25,26 EGFR copy number as determined 
by  fluorescence  in  situ  hybridization  (FISH),  and 
KRAS gene mutation status. Among patients treated 
with cetuximab or panitumumab, a high EGFR gene 
copy number determined by FISH has been associ-
ated with higher tumor RR, and prolongation of dis-
ease-free survival and OS.
In contrast, patients with tumors having mutations 
in KRAS appear to be relatively resistant to treatment 
with cetuximab or panitumumab, with lower RRs and 
poorer survival. These and other molecular features 
may help define a subset of patients who will derive 
benefit from treatment with an EGFR inhibitor.
While initial studies attempted to detect EGFR on 
the surface of tumor cells by immunohistochemical 
techniques, subsequent retrospective analysis found 
no correlation between EGFR expression, as assessed 
by  immunohistochemistry  (IHC),  and  clinical  out-
come.27 Therefore, the need for other   predictive factors 
has become imperative in order to avoid unnecessary 
toxicities and waste of resources.
KRAS mutations occur in about 45% of primary 
CRC, and such mutations have been demonstrated to 
be predictors of resistance to anti-EGFR monoclonal 
antibodies. In the presence of specific mutations of 
the KRAS gene, the Ras protein is constitutively acti-
vated and subsequent signaling events are not regu-
lated and independent from EGFR control.2,27
Several studies carried out in patients with mCRC 
have shown resistance to cetuximab in the presence 
of KRAS mutations (point mutations in codons 12 
and 13).
In this way, the recent addition to this therapeu-
tic arsenal, panitumumab, which is the first human 
monoclonal  antibody  directed  against  EGFR,  has 
shown inefficacy in patients diagnosed with mCRC 
with KRAS mutations and therefore this drug was 
approved  for  the  treatment  of  patients  with  wild-
type  KRAS  who  have  proven  to  be  resistant  to 
chemotherapy.
A new problem has emerged with this mutational 
analysis. Where should we determine the mutational 
KRAS status: at the primary tumor or at the metasta-
sis? In all these studies, the mutational analysis was 
conducted almost exclusively on primary tumors.1 It 
has been shown that primary CRCs may differ from 
their metastases in terms of EGFR, assessed by IHC. 
Although it is well known that KRAS mutations occur 
in the first stages of CRC progression, additional data 
have demonstrated that the frequency of KRAS muta-
tions in lymph node metastases is higher than in the 
related primary CRC. The study by Santini et al28 
which tried to verify if the point explained above is 
right,  have  concluded  that  the  detection  of  KRAS 
mutations in either primary or metastatic tumors from 
patients with CRC is concordant, and this evaluation 
could be used as predictor of response to cetuximab 
and panitumumab.
With these results in mind, we have to consider why 
some patients with wild-type KRAS continue without 
responding to these monoclonal antibodies. As Drs 
Lindsey and Jimeno have explained, other parts of 
the EGFR signaling pathway have been evaluated as 
possible contributing factors. One of these potential 
factors is BRAF that acts as a downstream effector of 
KRAS. Mutation of this gene has resulted in pathway 
activation similar to that of induced by KRAS.Metastatic colorectal cancer: a commentary
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Several retrospective analyses have been carried 
out on patients with metastatic CRC after they were 
treated  with  cetuximab  or  panitumumab  to  evalu-
ate the effect of BRAF mutation. The mutation was 
found in several patients with wild-type KRAS and 
none of them responded to this treatment, and their 
PFS and OS were shorter when compared to patients 
with wild-type BRAF.1 When sorafenib, which is an 
RAF inhibitor, was added to an anti-EGFR monoclo-
nal antibody, the RR was improved in BRAF-mutated 
cells.29 Further trials will be necessary to assess this 
combination.30
The study published by Laurent-Puig et al31 tried 
to  discriminate  the  role  of  different  biomarkers  as 
predictive factors in mCRC. They evaluated tumors 
from 173 patients retrospectively. All but one of the 
patients received a cetuximab-based regimen as sec-
ond-line or greater therapy. KRAS and BRAF status, 
EGFR amplification and the expression of PTEN were 
assessed. In the 116 patients with KRAS wild-type 
tumors, BRAF mutations (n = 5) were weakly associ-
ated with a lack of response (P = 0.063) but strongly 
associated with a shorter PFS (P , 0.001) and OS 
(P , 0.001). Negative PTEN expression was found 
in 19.9% of cases and was associated with a shorter 
OS (P = 0.013). In te multivariate analysis, BRAF 
mutation and PTEN expression status were associated 
with OS. The authors concluded that BRAF status 
and cytoplasmic expression of PTEN were associated 
with outcome measures in wild-type KRAS patients 
treated with a cetuximab-based regimen.
Although these are very interesting results, subse-
quent studies in clinical trials will be required to con-
firm the clinical utility of these biomarkers.
On the other hand, as Lindsey and Jimeno have 
noted,  specific  mutations  of  the  PIK3CA  gene  are 
considered to be oncogenic in cellular models, and 
are  thought  to  be  associated  with  metastasis  and 
decreased apoptosis. Sartore-Bianchi et al32 explored 
the relevance of PIK3CA mutation. They carried out 
a retrospective analysis of 110 patients with mCRC 
who had previously been treated with panitumumab 
or cetuximab therapy. Of the 15 patients with PIK3CA 
mutations,  none  demonstrated  an  objective  tumor 
response to EGFR inhibitor therapy, and an overall 
trend of decreased PFS was observed. Others (e.g. 
Prenen et al) detected a 20% response to cetuximab 
in mCRC patients with PIK3CA mutations.33
With  all  these  data,  it  is  clear  that  the  era  of 
  pharmacogenomics has been widely heralded and it 
will represent the start of a new approach to cancer 
care. As Lindsey and Jimeno have concluded, panitu-
mumab is a very important new therapy in CRC not 
only due to its demonstrated activity but also its gen-
erally good tolerability. Also panitumumab has had an 
important role in the development of biomarker sci-
ence to predict subgroups of patients who are likely 
to benefit from these treatments.
Readers are recommended to refer colleagues to 
this review by Lindsey and Jimeno and to use it as a 
reference when treating mCRC patients.
Disclosure
This manuscript has been read and approved by the 
author. This paper is unique and is not under con-
sideration by any other publication and has not been 
published elsewhere. The author and peer reviewers 
of this paper report no conflicts of interest. The author 
confirms that they have permission to reproduce any 
copyrighted material.
References
  1.  Lindsey D, Jimeno A. Metastatic colorectal cancer: focus on panitumumab. 
Clinical Medicine Reviews in Oncology. 2010;2:109–21.
  2.  Wolpin BM, Mayer R. Systemic treatment of colorectal cancer. Gastroen-
terology. 2008;134(5):1296–310.
  3.  O´Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorec-
tal cancer: an update of recent clinical trials. Oncologist. 2008;13:1074–83.
  4.  Cejas P, López-Gómez M, Aguayo C, et al. KRAS mutations in primary col-
orectal cancer tumors and related metastases: a potential role in prediction 
of lung metastasis. PLoS ONE. 2009;12(4):e8199.
  5.  Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. 
Nat Med. 2003;9:669–76.
  6.  Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, 
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 
2004;350:2335–42.
  7.  Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in com-
bination with fluorouracil and leucovorin: an active regimen for first-line 
metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–8.
  8.  Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syn-
drome and bevacizumab. N Engl J Med. 2006;354:980–2.
  9.  Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II randomized 
trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with 
FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 
2003;21:60–5.
  10.  Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: 
the addition of bevacizumab to fluorouracil/leucovorin improves survival for 
patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–12.
  11.  Hurwitz  H,  Fehrenbacher  L,  Novotny W.  Bevacizumab  plus  irinotecan, 
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 
2004;350:2335–42.
  12.  Giantonio  BJ,  Catalano  PJ,  Meropol  NJ,  et  al.  High-dose  bevacizumab 
improves survival when combined with FOLFOX4 in previously treated 
advanced colorectal cancer: Results from the Eastern Cooperative Oncol-
ogy Group (ECOG) study E3200 (abstract). J Clin Oncol. 2005;23:1s.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  yours!  you retain copyright
http://www.la-press.com
Uña Cidón
60  Clinical Medicine Insights: Oncology 2010:4
  13.  Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of 
irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treat-
ment of metastatic colorectal cancer: results from the BICC-C Study. J Clin 
Oncol. 2007;25:4779–86.
  14.  Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combina-
tion with XELOX or FOLFOX4: updated efficacy results from XELOX-1/
NO16966, a randomized phase III trial in first-line metastatic colorectal 
cancer. J Clin Oncol. 2007;25(18S)Abstr 4028.
  15.  Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and 
cetuximab  plus  irinotecan  in  irinotecan-refractory  metastatic  colorectal 
  cancer. N Engl J Med. 2004;351(4):337–45.
  16.  Jonker D, O’Callaghan C, Karapetis C, et al. Cetuximab for the treatment of 
colorectal cancer. N Engl J Med. 2007;357(20):2040–8.
  17.  Venook A, Niedzwiecki D, Hollis D, et al. Phase III trial of irinotecan/5FU/
LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) = /− cetuximab for patients 
(pts)  with  untreated  metastatic  adenocarcinoma  of  the  colon  or  rectum 
(MCRC): CALGB 80203 preliminary results. J Clin Oncol. 2006;24:148s.
(abstr 3509).
  18.  van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of 
irinotecan and 5-FU/LV with or without cetuximab in the first line treatment 
of patients with metastatic colorectal cancer. J Clin Oncol. 2007;25(164s)
abstr 4000.
  19.  Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab 
monotherapy  in  patients  with  metastatic  colorectal  cancer.  Journal  of 
  Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 
16S, Part I of II (June 1 Supplement), 2005:3520.
  20.  van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of pani-
tumumab plus best supportive care compared with best supportive care 
alone in patients with chemotherapy-refractory metastatic colorectal cancer. 
J Clin Oncol. 2007;25:1658–64.
  21.  Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of 
chemotherapy, bevacizumab, and panitumumab compared with chemother-
apy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 
2009;27(5):672–80.
  22.  Douillard J, Siena S, Cassidy J, et al. Phase III study (PRIME/20050203) 
of panitumumab with FOLFOX4 compared to FOLFOX4 alone in patients 
with previously untreated metastatic colorectal cancer: Preliminary safety 
data. In: ASCO 2008 Gastrointestinal Cancers Symposium; 2008. Abstract 
n° 443. Orlando January 25–27.
  23.  Peeters M, Wilson G, Hotko Y, et al. Phase III study (20050181) of panitu-
mumab with FOLFIRI compared to FOLFIRI alone as second-line treatment 
in patients with metastatic colorectal cancer: Preliminary safety results. In: 
ASCO 2008 Gastrointestinal Cancers Symposium; 2008. Abstract n° 335. 
Orlando January 25–27.
  24.  Tan B, Zubal B, Hawkins W, et al. Preoperative FOLFOX plus cetuximab 
or panitumumab therapy for patients with potentially resectable hepatic col-
orectal metastases. In: ASCO 2009 Gastrointestinal Cancers Symposium; 
2009. Abstract 497. Orlando January 25–27.
  25.  Finocchiaro G, Cappuzzo F, Janne PA, et al. EGFR, HER2, KRAS as pre-
dictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol. 
2007;25(18S)Abstr 4021.
  26.  Hebbar M, Wacrenier A, Desauw C, et al. Lack of usefulness of epidermal 
growth factor receptor expression determination for cetuximab therapy in 
patients with colorectal cancer. Anticancer Drugs. 2006;17:855–7.
  27.  Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and 
panitumumab in colorectal cancer. J Clin Oncol. 28:1254–61.
  28.  Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status 
between primary colorectal tumors and related metastatic sites: implications 
for clinical practice. Oncologist. 2008;13:1270–5.
  29.  Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required 
for response to panitumumab or cetuximab in metastatic colorectal cancer. 
J Clin Oncol. 2008;26(35):5705–12.
  30.  CIG Media Group Selected clinical trials in colorectal cancer. Clin Colorectal 
Cancer. 2007;6(7):539.
  31.  Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and 
EGFR status in determining benefit from cetuximab therapy in wild-type 
KRAS metastatic colon cancer. J Clin Oncol. 2009;27(35):5924–30.
  32.  Sartore-Bianchi A,  Martini  M,  Molinari  F,  et  al.  PIK3CA  mutations  in 
colorectal cancer are associated with clinical resistance to EGFR-targeted 
monoclonal antibodies. Cancer Res. 2009;69(5):1851–7.
  33.  Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a 
major  determinant  of  resistance  to  the  epidermal  growth  factor  recep-
tor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 
2009;15(9):3184–8.